Biotcis: middle-to-macro biomolecular targeted covalent inhibitors possessing both semi-permanent drug action and stringent target specificity as potential antibody replacements

HIGHLIGHTS

• who: Jay Yang et al. from the Department of Engineering Science, Graduate School of Informatics and Engineering, University of Electro-Communications (UEC), Chofugaoka, Chofu, Japan have published the research work: bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements, in the Journal: (JOURNAL) of 20/Dec/2022
• what: Next, the authors focus on recent hot topics of middle-molecule-type TCIs, including a concept of a reversible TCIs where the pharmacological action can be easily and specifically reversed by an antidote. Given . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.